DK2504353T4 - Lipopeptidsammensætninger og tilsvarende fremgangsmåder - Google Patents

Lipopeptidsammensætninger og tilsvarende fremgangsmåder Download PDF

Info

Publication number
DK2504353T4
DK2504353T4 DK10832379.1T DK10832379T DK2504353T4 DK 2504353 T4 DK2504353 T4 DK 2504353T4 DK 10832379 T DK10832379 T DK 10832379T DK 2504353 T4 DK2504353 T4 DK 2504353T4
Authority
DK
Denmark
Prior art keywords
similar methods
lipopeptide compositions
lipopeptide
compositions
methods
Prior art date
Application number
DK10832379.1T
Other languages
Danish (da)
English (en)
Other versions
DK2504353T3 (en
Inventor
Gaauri Naik
Sophie Sun
Sandra O'connor
Original Assignee
Cubist Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2504353(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals Llc filed Critical Cubist Pharmaceuticals Llc
Publication of DK2504353T3 publication Critical patent/DK2504353T3/en
Application granted granted Critical
Publication of DK2504353T4 publication Critical patent/DK2504353T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10832379.1T 2009-11-23 2010-11-23 Lipopeptidsammensætninger og tilsvarende fremgangsmåder DK2504353T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Publications (2)

Publication Number Publication Date
DK2504353T3 DK2504353T3 (en) 2018-09-10
DK2504353T4 true DK2504353T4 (da) 2023-11-20

Family

ID=44060422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10832379.1T DK2504353T4 (da) 2009-11-23 2010-11-23 Lipopeptidsammensætninger og tilsvarende fremgangsmåder

Country Status (33)

Country Link
US (3) US8835382B2 (https=)
EP (2) EP2504353B2 (https=)
JP (3) JP6041673B2 (https=)
CN (3) CN102712677B (https=)
AR (2) AR079127A1 (https=)
AU (1) AU2010321531C1 (https=)
BR (1) BR112012012406B1 (https=)
CA (1) CA2781666C (https=)
CL (2) CL2012001336A1 (https=)
CO (1) CO6541585A2 (https=)
CR (1) CR20120271A (https=)
CY (1) CY1120854T1 (https=)
DK (1) DK2504353T4 (https=)
DO (1) DOP2012000140A (https=)
EC (1) ECSP12011939A (https=)
ES (1) ES2686331T5 (https=)
FI (1) FI2504353T4 (https=)
HR (1) HRP20181380T4 (https=)
HU (1) HUE039967T2 (https=)
IL (1) IL219891B (https=)
LT (1) LT2504353T (https=)
MX (1) MX2012005993A (https=)
NZ (1) NZ600118A (https=)
PE (2) PE20151717A1 (https=)
PL (1) PL2504353T5 (https=)
PT (1) PT2504353T (https=)
RS (1) RS57566B2 (https=)
RU (1) RU2607526C2 (https=)
SG (1) SG10201407724YA (https=)
SI (1) SI2504353T2 (https=)
TR (1) TR201812823T4 (https=)
TW (2) TWI606838B (https=)
WO (1) WO2011063419A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
RU2013157188A (ru) * 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
ES2655215T3 (es) * 2012-08-23 2018-02-19 Mylan Laboratories Ltd. Mejoramiento de la formulación inyectable de daptomicina
US9655946B2 (en) 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) * 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
SU1452484A3 (ru) 1984-10-09 1989-01-15 Эли Лилли Энд Компани (Фирма) Способ получени производных антибиотиков А-21978С, штамм стрептомицета SтRертомYсеS RoSeoSpoRUS, используемый дл получени антибиотических веществ А-21978С
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (https=) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
DK0640095T3 (da) 1992-04-20 1999-04-12 Abbott Lab Fremgangsmåde til fremstilling af vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001044274A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2401299T5 (es) * 2006-07-26 2016-04-06 Sandoz Ag Formulaciones de caspofungina
DK2084519T3 (da) 2006-10-10 2012-08-20 Los Alamos Nat Security Llc Røntgenfluorescens-analysefremgangsmåde
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
AU2008317307A1 (en) * 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2011062676A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
CN103379917B (zh) 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法

Also Published As

Publication number Publication date
HRP20181380T1 (hr) 2018-10-19
US8835382B2 (en) 2014-09-16
NZ600118A (en) 2014-08-29
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
ES2686331T5 (es) 2024-03-27
CA2781666A1 (en) 2011-05-26
AR079127A1 (es) 2011-12-28
WO2011063419A3 (en) 2011-10-13
DOP2012000140A (es) 2012-10-30
MX2012005993A (es) 2012-11-23
SG10201407724YA (en) 2014-12-30
JP6041673B2 (ja) 2016-12-14
EP2504353A2 (en) 2012-10-03
JP2013511557A (ja) 2013-04-04
EP2504353B2 (en) 2023-09-13
US9662397B2 (en) 2017-05-30
CN104056250A (zh) 2014-09-24
LT2504353T (lt) 2018-09-25
AU2010321531A1 (en) 2012-06-14
PE20121517A1 (es) 2012-11-26
CN108785654A (zh) 2018-11-13
PL2504353T5 (pl) 2023-11-20
RS57566B1 (sr) 2018-10-31
IL219891B (en) 2018-01-31
EP3417849A1 (en) 2018-12-26
CL2012001336A1 (es) 2012-10-05
BR112012012406A2 (pt) 2019-12-03
TW201703791A (zh) 2017-02-01
CL2015002412A1 (es) 2016-02-05
CY1120854T1 (el) 2019-12-11
ES2686331T3 (es) 2018-10-17
US9138456B2 (en) 2015-09-22
SI2504353T1 (sl) 2018-10-30
JP6088681B2 (ja) 2017-03-01
RS57566B2 (sr) 2023-12-29
JP6239167B2 (ja) 2017-11-29
HUE039967T2 (hu) 2019-02-28
DK2504353T3 (en) 2018-09-10
CO6541585A2 (es) 2012-10-16
EP2504353A4 (en) 2014-04-02
US20120270772A1 (en) 2012-10-25
US20160030577A1 (en) 2016-02-04
CN102712677B (zh) 2015-06-03
JP2016147874A (ja) 2016-08-18
RU2012126076A (ru) 2013-12-27
ECSP12011939A (es) 2012-07-31
CR20120271A (es) 2012-08-01
SI2504353T2 (sl) 2023-11-30
WO2011063419A2 (en) 2011-05-26
RU2607526C2 (ru) 2017-01-10
FI2504353T4 (fi) 2023-11-30
PL2504353T3 (pl) 2018-11-30
PE20151717A1 (es) 2015-11-19
AR123846A2 (es) 2023-01-18
AU2010321531A2 (en) 2014-10-30
JP2017075186A (ja) 2017-04-20
TWI548414B (zh) 2016-09-11
CA2781666C (en) 2017-02-21
TR201812823T4 (tr) 2019-02-21
PT2504353T (pt) 2018-10-18
BR112012012406B1 (pt) 2021-11-16
EP2504353B1 (en) 2018-07-11
AU2010321531C1 (en) 2020-10-01
US20140364380A1 (en) 2014-12-11
AU2010321531B2 (en) 2016-11-03
IL219891A0 (en) 2012-07-31
HRP20181380T4 (hr) 2023-11-10
CN102712677A (zh) 2012-10-03

Similar Documents

Publication Publication Date Title
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2419670T3 (da) Leveringsmetode og sammensætninger
SMT201600319B (it) Metodi di selezione e amplificazione di polinucleotidi
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
PL2496691T3 (pl) Terapeutyczne kompozycje nukleazy i sposoby
HUE065114T2 (hu) Monoklórtrifluorpropén vegyületek és készítmények és eljárások azok alkalmazásával
DK3190183T3 (da) Sammensætninger og fremgangsmåder omfattende proteasevarianter
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
PT2448582T (pt) Compostos e composições terapêuticas
BRPI1010079A2 (pt) composição e artigo
EP2515946A4 (en) NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS
BR112012002247A2 (pt) composição e artigo
DK2544679T3 (da) Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
DK2482841T4 (da) Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
BRPI1009446A2 (pt) Composições compreendendo monatina e cálcio
EP2512483A4 (en) BALAGLITAZON COMPOSITIONS AND METHOD THEREFOR
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
BR112012029669A2 (pt) composição e método
BR112013008812A2 (pt) composição e método
GB0901494D0 (en) Compositions and Methods